🇺🇸 FDA

Company profile · Sponsor

SUPERNUS

SUPERNUS PHARMACEUTICALS, INC.

SUPN · NYSE pharma ROCKVILLE, MD, USA
Pipeline
24
Drugs
1
Patents
8

Quick answer

SUPERNUS (SUPN) is a pharma company. headquartered in ROCKVILLE, MD, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 1 drug, and 8 patents to this profile..

Company facts

Ticker SUPN
Exchange NYSE
Company type pharma
Headquarters ROCKVILLE, MD, USA
SEC CIK 0001356576

Pipeline (24)

Search pipeline →

  1. Brexanolone

    SUPERNUS

    Post Partum Depression

    phase 3 small molecule completed

    1 trial

  2. MYOBLOC

    SUPERNUS

    Sialorrhea

    phase 3 small molecule completed

    2 trials

  3. MYOBLOC Low Dose

    SUPERNUS

    Sialorrhea

    phase 3 small molecule terminated

    1 trial

  4. Oxcarbazepine XR

    SUPERNUS

    Partial Epilepsy

    phase 3 small molecule completed

    1 trial

  5. Phase 2; Low Dose MYOBLOC

    SUPERNUS

    Spasticity

    phase 3 small molecule active

    1 trial

  6. Phase 2; Low Dose MYOBLOC (15,000 Units)

    SUPERNUS

    Spasticity

    phase 3 small molecule terminated

    1 trial

  7. Placebo

    SUPERNUS

    Epilepsies, Partial

    phase 3 small molecule completed

    1 trial

  8. Placebo

    SUPERNUS

    Postpartum Depression

    phase 3 small molecule completed

    2 trials

  9. Placebo

    SUPERNUS

    Attention-Deficit/Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    2 trials

  10. Placebo

    SUPERNUS

    ADHD

    phase 3 small molecule completed

    5 trials

  11. SAGE-547

    SUPERNUS

    Super-refractory Status Epilepticus

    phase 3 small molecule completed

    2 trials

  12. SAGE-718

    SUPERNUS

    Huntington's Disease

    phase 3 small molecule terminated

    2 trials

  13. SPN-810

    SUPERNUS

    Attention Deficit Hyperactivity Disorder

    phase 3 small molecule terminated

    1 trial

  14. SPN-810

    SUPERNUS

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule terminated

    2 trials

  15. SPN-810 (18 mg)

    SUPERNUS

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    2 trials

  16. apomorphine infusion

    SUPERNUS

    Idiopathic Parkinson's Disease

    phase 3 small molecule active

    1 trial

  17. BIS-001ER

    SUPERNUS

    Focal Impaired Awareness Seizures

    phase 2 small molecule active

    1 trial

  18. Botulinum Toxin Type B (Myobloc)

    SUPERNUS

    Drooling

    phase 2 mab completed

    1 trial

  19. Brexanolone

    SUPERNUS

    Tinnitus

    phase 2 small molecule completed

    1 trial

  20. Gocovri (extended-release amantidine)

    SUPERNUS

    Radiation Encephalopathy

    phase 2 small molecule active

    1 trial

  21. Huperzine A, Huperzine A, Capsules, Huperzine A

    SUPERNUS

    Focal Onset Seizures

    phase 2 small molecule active

    1 trial

  22. IR Viloxazine

    SUPERNUS

    Attention-Deficit/Hyperactivity Disorder (ADHD)

    phase 2 small molecule completed

    1 trial

  23. IR-TPM (Topamax)

    SUPERNUS

    Migraine

    phase 2 small molecule terminated

    1 trial

  24. Molindone

    SUPERNUS

    Impulsive Aggression Comorbid With ADHD in Children

    phase 2 small molecule completed

    1 trial

Drugs (1)

Search drugs →

  1. viloxazine hydrochloride

    VILOXAZINE HYDROCHLORIDE

    ORAL approved

Patents (8)

Search patents →

  1. US 12121523

    Method of treatment of attention deficit/hyperactivity disorder (ADHD)

    Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11911368

    Method of treatment of CNS disorders

    Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11896599

    Modified release preparations containing oxcarbazepine and derivatives thereof

    Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11638708

    Method of treatment of aggression

    Expires Mon Apr 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11458143

    Method of treatment of attention deficit/hyperactivity disorder (ADHD)

    Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11351120

    Use of higher doses of modified release huperzine formulations

    Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11324753

    Method of treatment of attention deficit/hyperactivity disorder (ADHD)

    Expires Mon May 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11166960

    Modified release preparations containing oxcarbazepine and derivatives thereof

    Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is SUPERNUS?

SUPERNUS (SUPN) is a pharma company. headquartered in ROCKVILLE, MD, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 1 drug, and 8 patents to this profile..

What pipeline programs does SUPERNUS sponsor?

We track 24 ClinicalTrials.gov-linked programs for SUPERNUS, including Brexanolone and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does SUPERNUS company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.